SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K Current Report was filed on September 10, 2025, by Athira Pharma, Inc. (Note: The request metadata referenced "Leonabio, Inc.", but the filing text explicitly identifies the registrant as Athira Pharma, Inc.). The report details a material corporate action regarding the company's capital structure.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate governance action.
Material Changes
The primary material change is the implementation of a 10-for-1 reverse stock split, effective as of 5:00 p.m. Eastern Time on September 17, 2025. Key structural changes include:
- Authorized Common Stock: Reduced from 900,000,000 to 90,000,000 shares.
- Total Authorized Capital Stock: Reduced from 1,000,000,000 to 190,000,000 shares.
- Share Consolidation: Every 10 issued and outstanding shares will be combined into 1 share.
- Fractional Shares: Will be paid out in cash rather than issued as fractional stock.
- Trading Details: Post-split trading on the Nasdaq Capital Market is expected to begin on September 18, 2025, under the symbol "ATHA".
- CUSIP Number: Will change to 04746L203.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the information is qualified by reference to the full Certificate of Amendment. The reverse split was approved by stockholders at the Annual Meeting on May 29, 2025.
Investor Verification Checklist
- Verify the effective date of the reverse split (September 17, 2025) and the start of post-split trading (September 18, 2025).
- Confirm the new CUSIP number (04746L203) with brokerage accounts to ensure proper settlement.
- Review the treatment of fractional shares, which will be settled in cash.
- Check for proportional adjustments to outstanding options and restricted stock units (RSUs) in the company's equity incentive plans.
- Confirm that no action is required for stockholders holding shares in book-entry form or brokerage accounts.